Efficacy and safety of daclatasvir plus asunaprevir for Korean patients with HCV genotype Ib infection: a retrospective multi-institutional study
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Cho, Byeong Wook | - |
dc.contributor.author | Kim, Seok Bae | - |
dc.contributor.author | Song, Il Han | - |
dc.contributor.author | Lee, Sae Hwan | - |
dc.contributor.author | Kim, Hong Soo | - |
dc.contributor.author | Lee, Tae Hee | - |
dc.contributor.author | Kang, Young Woo | - |
dc.contributor.author | Kim, Seok Hyun | - |
dc.contributor.author | Lee, Byung Seok | - |
dc.contributor.author | Chae, Hee Bok | - |
dc.date.accessioned | 2021-08-11T15:24:22Z | - |
dc.date.available | 2021-08-11T15:24:22Z | - |
dc.date.issued | 2017-03 | - |
dc.identifier.issn | 2287-2728 | - |
dc.identifier.issn | 2287-285X | - |
dc.identifier.uri | https://scholarworks.bwise.kr/sch/handle/2021.sw.sch/7771 | - |
dc.description.abstract | Background/Aims: The combination of daclatasvir (DCV) and asunaprevir (ASV) has demonstrated a high sustained virologic response at 12 weeks (SVR12) and a low rate of adverse events in previous clinical studies. The purpose of this study was to clarify the results of treatment and side effects in Korean patients with chronic hepatitis C virus (HCV) genotype Ib infection. Methods: We retrospectively analyzed clinical data from chronic HCV genotype Ib patients treated with DCV+ASV from August 2015 to September 2016 at five hospitals in the Daejeon-Chungcheong area. Results: A total of 152 patients were examined for resistance associated variants (RAVs). Among them, 15 (9.9%) were positive for Y93 and one (0.7%) was positive for L31. Of 126 patients treated with DCV+ASV, 83 patients completed treatment and 76 patients were included in safety and efficacy analysis. Five (6.6%) were positive for Y93 and 12 (15.8%) exhibited cirrhotic change. DCV+ASV was the first-line treatment for 58 (76.3%) patients. Eleven (14.5%) patients relapsed after previous treatment that included interferon and seven (9.2%) of these patients were found to be intolerant of interferon. Adverse events occurred in 10 (13.2%) patients and two patients stopped the medication because of severe itching and skin rash. SVR12 was 89.5% (68/76) in all patients and 91.5% (65/71) in RAV-negative patients. Conclusions: DCV+ASV showed good efficacy in patients with HCV Ib infection in Korea. Close monitoring is needed for severe adverse events and treatment failure, which were uncommon. | - |
dc.format.extent | 6 | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | 대한간학회 | - |
dc.title | Efficacy and safety of daclatasvir plus asunaprevir for Korean patients with HCV genotype Ib infection: a retrospective multi-institutional study | - |
dc.type | Article | - |
dc.publisher.location | 대한민국 | - |
dc.identifier.doi | 10.3350/cmh.2016.0053 | - |
dc.identifier.wosid | 000407835300008 | - |
dc.identifier.bibliographicCitation | Clinical and Molecular Hepatology, v.23, no.1, pp 51 - 56 | - |
dc.citation.title | Clinical and Molecular Hepatology | - |
dc.citation.volume | 23 | - |
dc.citation.number | 1 | - |
dc.citation.startPage | 51 | - |
dc.citation.endPage | 56 | - |
dc.type.docType | Article | - |
dc.identifier.kciid | ART002206800 | - |
dc.description.isOpenAccess | N | - |
dc.description.journalRegisteredClass | scopus | - |
dc.description.journalRegisteredClass | esci | - |
dc.description.journalRegisteredClass | kci | - |
dc.relation.journalResearchArea | Gastroenterology & Hepatology | - |
dc.relation.journalWebOfScienceCategory | Gastroenterology & Hepatology | - |
dc.subject.keywordPlus | DIRECT-ACTING ANTIVIRALS | - |
dc.subject.keywordPlus | HEPATITIS-C PATIENTS | - |
dc.subject.keywordPlus | 1B | - |
dc.subject.keywordPlus | RESISTANCE | - |
dc.subject.keywordPlus | VARIANTS | - |
dc.subject.keywordAuthor | Daclatasvir | - |
dc.subject.keywordAuthor | Asunaprevir | - |
dc.subject.keywordAuthor | Hepatitis C, Chronic | - |
dc.subject.keywordAuthor | Korea | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(31538) 22, Soonchunhyang-ro, Asan-si, Chungcheongnam-do, Republic of Korea+82-41-530-1114
COPYRIGHT 2021 by SOONCHUNHYANG UNIVERSITY ALL RIGHTS RESERVED.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.